Retrophin, Inc. (OTCQB: RTRX) is a publicly-traded New York-based biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases. Retrophin is currently developing treatments for Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and other catastrophic diseases.

RECENT NEWS May 8, 2013 - Retrophin Names Marc L. Panoff as Chief Financial Officer
Apr 25, 2013 - Retrophin Names Horacio Plotkin, M.D. as Chief Medical Officer
Apr 8, 2013 - Retrophin Sponsors Seventh International NBIA Disorders Association Family Conference
Mar 11, 2013 - Retrophin Announces Positive Results from Preclinical Studies of RE-024 for PKAN
Mar 8, 2013 - Retrophin to Present at 25th Annual ROTH Conference
Feb 12, 2013 - Retrophin Raises $10.0 Million in Private Placement
Feb 4, 2013 - Retrophin to Present at the 15th Annual BIO CEO & Investor Conference
Dec 18, 2012 - Retrophin Completes Reverse Merger with Desert Gateway, Inc.
Jul 16, 2012 - Retrophin and St. Jude Children's Research Hospital to Collaborate on Rare Disease
May 7, 2012 - Retrophin, LLC Completes Series A Financing
Mar 12, 2012 - BioWorld Today - Shkreli's Retrophin Eyes Public Markets to Fund Rare Diseases
Feb 21, 2012 - Ligand Licenses DARA Program to Retrophin